Information Provided By:
Fly News Breaks for November 2, 2016
RGLS
Nov 2, 2016 | 09:19 EDT
As reported previously, Cowen's Dr. Eric Schmidt downgrade Regulus to Market Perform from Outperform. The analyst cited a longer than expected delay in responding to the FDA's clinical hold on RG-101 and also cited the suspension in dosing of RG-102 which will push out its proof-of-concept data to 2018.
News For RGLS From the Last 2 Days
There are no results for your query RGLS